Feigal unveils a new vision of US regulation
This article was originally published in Clinica
Executive Summary
The US FDA has adopted a strategic vision for medical device regulation that calls for continuous scrutiny of medical products throughout their life cycles rather than separating the agency's remit into pre- and postmarket activities.